Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

Is BPC 157 a PED? The Unflinching Answer for Researchers

Let's cut straight to it. The buzz around BPC 157 is almost deafening these days, and with it comes a sprawling cloud of questions, half-truths, and outright confusion. You've probably seen it mentioned in forums, discussed by biohackers, and whispered about i

Let's cut straight to it. The buzz around BPC 157 is almost deafening these days, and with it comes a sprawling cloud of questions, half-truths, and outright confusion. You've probably seen it mentioned in forums, discussed by biohackers, and whispered about in athletic circles. The excitement is palpable, but so is the uncertainty. At the heart of it all is one persistent, critical question: is BPC 157 considered a PED?

It’s a simple question with a surprisingly complicated answer. And frankly, getting this wrong has significant consequences, whether you're an athlete, a coach, or—most importantly to us—a dedicated researcher. Our team at Real Peptides has spent years navigating the intricate world of peptide science. We've seen compounds rise from obscurity to become subjects of groundbreaking studies. We’ve also seen the damage that misinformation can do. That’s why we’re here to provide an unflinching, expert-driven look at where BPC 157 stands, separating the regulatory facts from the speculative fiction.

First, What Exactly Is BPC 157?

Before we can even touch the PED classification, we need to be on the same page about what this molecule actually is. It's not a steroid. It's not a hormone. BPC 157, which stands for Body Protection Compound 157, is a synthetic peptide chain composed of 15 amino acids. Its origin story is fascinating; it's a small, stable fragment derived from a protein found naturally in human gastric juice.

Think about that for a moment. A substance originally isolated from stomach acid is now at the forefront of regenerative medicine research. That's the power of peptide science. Initially, researchers were intrigued by its powerful cytoprotective effects—its ability to protect cells from various forms of damage. This led to a cascade of studies exploring its potential to accelerate healing in a wide variety of tissues, from tendons and ligaments to muscles and even the gut lining. We're talking about a compound that appears to have a systemic, organizing effect on the body's repair processes.

Its proposed mechanisms are incredibly complex and what makes it such a compelling subject for scientific inquiry. Researchers have observed its influence on angiogenesis (the formation of new blood vessels), its modulation of growth factors like Vascular Endothelial Growth Factor (VEGF), and its interaction with the nitric oxide (NO) pathway. For any lab conducting studies on tissue repair or inflammation, a high-purity compound like our BPC 157 Peptide represents a powerful tool for investigation. It offers a window into the body's innate healing architecture. But this remarkable potential is precisely what puts it under the microscope of anti-doping agencies.

Defining the Term 'Performance-Enhancing Drug'

Here’s where the lines get blurry for many people. The term 'PED' often conjures images of anabolic steroids and massive, bulky muscles. That's a very narrow, outdated view. The reality is far broader.

Organizations like the World Anti-Doping Agency (WADA) have a much more sophisticated and encompassing definition. They don't just ban things that make you stronger or faster in a direct, brute-force way. WADA's criteria for placing a substance on its Prohibited List are based on meeting any two of the following three conditions:

It has the potential to enhance or enhances sport performance. This is the big one. Notice the word 'potential.' It doesn't have to be definitively proven in large-scale human trials. If credible scientific evidence suggests it could provide a competitive edge, it meets this criterion. This includes accelerating recovery, which is a massive performance advantage.

It represents an actual or potential health risk to the athlete. This is about safety. If a substance hasn't been approved by a major governmental health authority for human therapeutic use, it's often considered to carry a potential risk.

It violates the spirit of sport. This is the ethical component. It refers to the essence of Olympism, the concept of fair play, and the pursuit of human excellence through the dedicated perfection of natural talent.

This framework is critical. A substance doesn't need to be a steroid to be a PED. It doesn't even need to be 'dangerous' in the conventional sense. If it has the potential to boost performance and isn't an approved medication, it's almost certainly going to land on the prohibited list. That's the key.

The Verdict: Is BPC 157 Considered a PED?

Yes. Unambiguously, yes.

According to the World Anti-Doping Agency, BPC 157 is a prohibited substance at all times for all athletes. It’s not categorized with anabolic agents or hormones. Instead, it falls under the catch-all category of S0 Unapproved Substances. This is a critical distinction. This category is for any pharmacological substance that is not addressed by any of the subsequent sections of the Prohibited List and is not approved for human therapeutic use by any governmental regulatory health authority. Basically, if it's a drug-like substance in development, in pre-clinical testing, or otherwise not officially on the market for people, it’s banned.

Why? It hits those WADA criteria perfectly. Let's break it down from their perspective:

Potential to Enhance Performance? Absolutely. The very reason researchers are so excited about BPC 157—its potential to dramatically accelerate the healing of tendons, ligaments, and muscle—is a monumental performance enhancer. For an athlete, recovery isn't just downtime; it's the entire engine of progress. The ability to recover faster from grueling workouts or bounce back from nagging injuries is a formidable competitive advantage. It allows for higher training volume and intensity. That's a performance enhancement, full stop.

Potential Health Risk? Yes. From a regulatory standpoint, BPC 157 has not undergone the rigorous, multi-phase clinical trials required by agencies like the FDA for approval as a human therapeutic drug. While pre-clinical and animal studies have shown a strong safety profile, it hasn't cleared that final, official hurdle. For WADA, the absence of this approval automatically flags it as a potential risk.

So, BPC 157 meets at least two of the three criteria, making its inclusion on the Prohibited List a straightforward decision for anti-doping bodies. It’s not about whether it 'feels' like a steroid or not. It's about a systematic application of the rules. Our team has found that this is the single biggest point of confusion. People get stuck on the mechanism and miss the regulatory reality. The fact that it works on a different pathway than traditional PEDs is irrelevant to its status.

BPC 157 vs. Anabolic Steroids: A Tale of Two Categories

To truly grasp the nuance here, it helps to see how BPC 157 stacks up against the classic PEDs everyone thinks of. They both fall under the broad PED umbrella, but they live in completely different neighborhoods. Our experience shows that clarifying this difference is essential for researchers to understand the unique properties they are investigating.

Mechanism of Action

Modulates growth factors, promotes angiogenesis, interacts with nitric oxide pathways for tissue repair.

Directly binds to androgen receptors to increase muscle protein synthesis and nitrogen retention.

Primary Research Focus

Systemic healing, cytoprotection, tendon/ligament repair, gut health, and anti-inflammatory effects.

Muscle hypertrophy (growth), increased strength, and enhanced red blood cell production.

WADA Status

Prohibited under S0 Unapproved Substances. Banned because it's not approved for human use.

Prohibited under S1 Anabolic Agents. Banned for its direct and powerful anabolic effects.

Legal Status (Human Use)

Not approved by the FDA. Sold legally as a research chemical not for human consumption.

Controlled substances. Illegal to possess or distribute without a valid prescription.

Common Misconception

That it's 'natural' or 'just a healing peptide' and therefore not a PED.

That all PEDs are steroids. Steroids are just one class of a much larger group of substances.

This table makes it crystal clear. Lumping BPC 157 in with testosterone is like comparing a specialized surgical tool to a sledgehammer. Both can be used to alter the structure, but their purpose, mechanism, and precision are worlds apart. The classification as a PED is a regulatory and ethical one, not necessarily a pharmacological one.

The Real Story: BPC 157's Power in a Research Setting

Now, let's pivot away from the world of sports and into our world: the laboratory. This is where the story of BPC 157 gets truly exciting. Frankly, its PED status is almost a footnote in the context of its scientific potential.

For researchers, BPC 157 isn't about gaining an edge; it's about understanding and potentially unlocking the body's fundamental repair mechanisms. The studies are compelling. We're seeing investigations into its ability to heal transected Achilles tendons in rats, protect organs from drug-induced damage, and even ameliorate inflammatory bowel disease symptoms in animal models. It appears to be a master conductor of the healing orchestra.

This is why purity and quality are non-negotiable. When a lab is conducting sensitive experiments, any impurity or incorrect peptide sequence can completely invalidate the results. It introduces variables that make the data unreliable. That's why at Real Peptides, our entire process is built around precision. From small-batch synthesis to rigorous third-party testing, we ensure that the BPC 157 Capsules and injectable peptides we provide are exactly what they claim to be. It’s a commitment we extend across our full range of research peptides. When you're trying to uncover biological truth, there's no room for error.

Researchers are using BPC 157 to ask profound questions:

Can we find new pathways to accelerate recovery from tendon and ligament surgeries?

Is it possible to develop therapies that protect the digestive system from the harsh side effects of other medications?

Could this peptide lead to novel treatments for chronic inflammatory conditions?

These aren't questions about winning a race. They're questions about improving human health on a fundamental level. The 'PED' label, while accurate in its own context, fails to capture the immense promise this compound holds for the future of medicine. It’s a classic case of a tool being defined by one specific, prohibited application rather than its vast spectrum of potential uses.

Understanding the Regulatory Maze

So, if it’s banned by WADA, does that make it illegal? This is another critical point of confusion we need to clear up.

Banned and illegal are not the same thing.

WADA's Prohibited List is a set of rules for a specific group: athletes competing in sports that adhere to the WADA code. It is not a law of the land. The legal status of BPC 157 is different. In the United States, it is not a controlled substance. However, it is also not an FDA-approved drug. This places it in a specific category: an investigational chemical.

It is legal to purchase and possess BPC 157 for the explicit purpose of in-vitro or laboratory research. It is not legal to market, sell, or purchase it for human consumption. This is why every reputable supplier, including us, labels our products with "For Research Use Only." This isn't just a suggestion; it's a critical legal and ethical boundary. Our clients are universities, private labs, and medical research institutions who understand this distinction perfectly. They aren't trying to skirt athletic regulations; they're trying to push the boundaries of science.

We can't stress this enough: anyone representing BPC 157 as a 'supplement' or for personal use is operating outside of these established guidelines. It undermines the legitimate research and creates the very confusion that leads to these questions in the first place.

A Broader Look: Other Peptides in the Spotlight

The story of BPC 157 doesn't exist in a vacuum. It's part of a larger, rapidly evolving landscape of research peptides, many of which also face scrutiny from regulatory bodies. Take TB 500 Thymosin Beta 4, for example. It's another powerful healing peptide, often researched alongside BPC 157, and it too is on the WADA Prohibited List for similar reasons.

Then you have the growth hormone secretagogues, like the combination of CJC1295 Ipamorelin. These peptides work by stimulating the body's own production of growth hormone. Because of their powerful effects on muscle growth and recovery, they are explicitly banned under section S2 of the WADA list. Understanding these different classifications helps researchers appreciate the diverse mechanisms at play across the peptide family.

Each of these compounds, from healing factors to secretagogues, represents a unique avenue of scientific exploration. The regulatory challenges are simply part of the territory when you're working on the cutting edge. It requires a commitment to ethical sourcing and responsible handling—a commitment that is at the core of everything we do.

While the question 'is BPC 157 considered a PED' has a simple yes-or-no answer, the context surrounding that answer is what truly matters. It's a PED in the world of competitive sports. But in the world of biomedical research, it's a key that could unlock a new generation of regenerative therapies. The two realities coexist. For the scientific community, focusing on its research potential, while respecting its regulatory status, is the only path forward. It's about harnessing its power responsibly to uncover what's possible. For researchers ready to explore these frontiers with impeccable purity, we're here to help you [Get Started Today].

Frequently Asked Questions

No, BPC 157 is not a steroid. It’s a synthetic peptide chain made of 15 amino acids, derived from a protein found in gastric juice. Its mechanism of action is completely different from anabolic steroids.

WADA bans substances that meet two of three criteria: performance enhancement, health risk, or violating the spirit of sport. BPC 157 is banned as an ‘Unapproved Substance’ because it has the potential to enhance recovery (a performance advantage) and is not approved for human therapeutic use.

Yes, anti-doping agencies have developed specific tests to detect BPC 157 in urine and blood samples. An athlete subject to WADA code testing can be sanctioned if it is found in their system.

It is legal to purchase and possess BPC 157 for legitimate laboratory and research purposes only. It is not approved by the FDA for human consumption, and marketing it as a supplement is not permitted.

Both are peptides researched for their healing properties, but they are different molecules with distinct structures. While often studied together, like in our [Wolverine Peptide Stack](https://www.realpeptides.co/products/wolverine-peptide-stack/), they may have complementary but different mechanisms of action. Both are on the WADA Prohibited List.

In a research context, BPC 157 is studied in various forms, including injectable solutions and oral capsules. The administration method depends entirely on the specific goals and design of the research protocol.

This label signifies that the substance is intended for laboratory, in-vitro, or pre-clinical research and not for human or veterinary therapeutic use. It confirms the product is a high-purity chemical for scientific investigation, not a supplement or drug.

BPC 157 is a synthetic peptide. While it is a fragment derived from a naturally occurring protein in the stomach, the version used in research is synthesized in a lab to ensure stability and purity.

Scientific research is exploring BPC 157’s potential in a wide range of areas, including tendon and ligament healing, muscle repair, gut health (like IBD), and protecting organs from drug-induced damage.

No, not all peptides are banned. The WADA Prohibited List targets specific peptides that have a performance-enhancing effect, such as growth hormone secretagogues, certain healing factors like BPC 157, and others that are unapproved for human use.

Our team recommends only sourcing from reputable suppliers who provide third-party lab testing results (Certificates of Analysis) for each batch. At Real Peptides, this transparency is standard practice to guarantee purity and accuracy for your research.

No, it would not appear on a standard workplace or clinical drug test. It requires a specific, advanced anti-doping screen designed to look for peptide-based performance enhancers.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosing Ranges and Receptor Saturation Dynamics

Dose selection for combining BPC-157 LL-37 synergy dosing timing must account for receptor saturation at the subcutaneous injection site. BPC-157's effective range in animal models spans 1–10mcg/kg body weight. For a 70kg human equivalent dose calculation using the FDA-recommended allometric scaling factor (dividing animal dose by 6.2 for rats), this translates to approximately 250–500mcg per injection. Higher doses don't produce proportionally greater effects because VEGFR2 density at the capillary endothelium is finite. Once receptors are saturated, excess peptide diffuses systemically without additional local angiogenic benefit. LL-37's dose-response curve follows a different pattern. Antimicrobial activity peaks at 2–5μM local concentration, but immune-modulating effects (chemotaxis, cytokine regulation) occur at lower thresholds. 200–400mcg subcutaneous injection produces plasma concentrations in the 0.5–1.2μM range, sufficient for FPRL1 activation without triggering the inflammatory overshoot observed at doses above 600mcg. We've found that exceeding 500mcg LL-37 per injection increases injection site erythema and delays the transition from inflammation to proliferation phase. The opposite of the intended effect. The critical error most protocols make: dosing both peptides at their upper range simultaneously. A 500mcg BPC-157 + 400mcg LL-37 co-injection creates local peptide concentrations that compete for subcutaneous diffusion pathways. BPC-157 binds heparan sulfate …
STORAGE

The Blunt Truth About BPC-157 Storage

Here's the honest answer: most peptide storage failures happen because researchers underestimate how fragile these compounds are. BPC-157 isn't a small-molecule drug that tolerates a few degrees of variance. It's a 15-amino-acid chain held together by non-covalent forces that break the moment thermal energy exceeds bonding strength. Refrigeration isn't 'recommended'. It's the minimum requirement to prevent immediate degradation. If you're handling peptides casually, storing them next to food in a frequently opened fridge, or assuming 'cool and dark' is good enough, you're working with degraded material. The gap between proper peptide handling and what many assume is acceptable costs labs thousands in wasted compounds annually.
02

Question drills

Open a question for its connected answer.

01Frequently asked questions about BPC 157 for immune support+

Do you still have unanswered questions? Perhaps you need some additional information on BPC 157 immune support. Here are a few points that may help: Can BPC 157 improve immune function? BPC 157 immune system can improve with inflammation regulation and endothelial tissue protection. Combined with maintaining organ resilience, immune responses remain controlled. Is BPC 157 safe for post-COVID recovery? Evidence of BPC 157 covid and subsequent recovery remains preclinical. There are no large human trials to support the safety or effectiveness. The interest stems from theoretical anti-inflammatory and vascular effects. How long does it take to see effects on inflammation? Preclinical data and practitioner observations suggest effects may occur within days. Tissue repair effects appear to take a few weeks, with individual responses varying. How should BPC 157 be administered for best results? There is no standardized protocol for BPC 157 dosage. Subcutaneous injection and oral use depend on their goals. A qualified professional should always supervise administration.

SOURCE / livvnatural.com ↗
02What If I'm Switching Reconstitution Volumes Mid-Protocol?+

Recalculate your dose in ticks for the new concentration before drawing—switching from 2mL to 1mL reconstitution doubles your peptide concentration, meaning the same 10-tick draw now delivers twice the BPC-157 mass. A 250mcg dose at 2.5mg/mL concentration (2mL reconstitution) requires 10 ticks. The same 250mcg dose at 5mg/mL concentration (1mL reconstitution) requires only 5 ticks. Failing to adjust tick count when changing concentrations is the most common cause of accidental dose doubling in multi-vial protocols.

SOURCE / realpeptides.co ↗
03What If the Peptide I Receive Doesn't Match Research-Grade Specifications?+

BPC-157 is sold by numerous suppliers without third-party purity verification. Research-grade peptides require HPLC (high-performance liquid chromatography) purity testing and mass spectrometry confirmation of amino-acid sequence. Peptides below 98% purity contain manufacturing byproducts that can trigger immune responses or compete for receptor binding. Real Peptides provides batch-specific HPLC certificates with every order. The verification standard necessary for reproducible research outcomes.

SOURCE / realpeptides.co ↗
04What If I'm Concerned About Immunosuppression from Biologics?+

That concern is clinically valid. TNF inhibitors and JAK inhibitors increase infection risk, particularly reactivation of latent tuberculosis or opportunistic infections. BPC-157 studied rheumatoid arthritis through a non-immunosuppressive mechanism, which theoretically avoids that risk. However, the peptide's safety profile in immunocompromised patients or those with active infections is unknown. If infection risk is driving your search for alternatives, consider conventional DMARDs like hydroxychloroquine or sulfasalazine, which carry lower immunosuppression burden than biologics, before moving to unproven peptides.

SOURCE / realpeptides.co ↗
05What If I Only Have Access to Standard Insulin Syringes for Both Reconstitution and Injection?+

Use them for injection only—never for reconstitution. Draw bacteriostatic water with the insulin syringe, but instead of puncturing the peptide vial, transfer the water to a separate sterile container, then draw it back through a filtered needle (0.22 micron) if available before adding to the vial. This two-step process prevents the insulin needle from coring the stopper during the high-pressure injection phase of reconstitution. It adds 30-45 seconds to your protocol but eliminates 60-80% of particulate contamination compared to direct insulin syringe reconstitution. If you must use insulin syringes for direct reconstitution, puncture the stopper at a perpendicular angle and avoid lateral needle movement inside the vial—side-to-side motion is what shaves rubber particles loose.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Related Research Articles

What Is BPC-157? Complete Research Introduction for Laboratory Scientists BPC-157 Reconstitution Calculator: Dose and Volume Reference Tool

RESEARCH

BPC-157 VEGFR2 Research: Cell Model Pathway and Gastrointestinal Studies

BPC-157 VEGFR2 Research: Cell Model Pathway and Gastrointestinal Studies BPC-157 is a research compound studied in cell-based assay formats for its VEGFR2 receptor pharmacology, FAK/paxillin signalling, and NO synthase pathway modulation. Published in vitro research characterises its molecular interactions, binding affinity profiles, and downstream pathway engagement in defined cell model systems under controlled laboratory conditions. Receptor Pharmacology and Mechanism of Action VEGFR2 Pathway Engagement BPC-157 demonstrates selective interaction with vascular endothelial growth factor receptor 2 (VEGFR2) in cell-based assay systems. The peptide exhibits concentration-dependent binding affinity to VEGFR2, with kinetic studies revealing saturable binding characteristics typical of receptor-mediated interactions. Fluorescence polarisation assays and radioligand binding studies establish the compound's pharmacological profile at this receptor target. The VEGFR2 activation cascade initiated by BPC-157 involves autophosphorylation of tyrosine residues within the receptor's intracellular domain. This phosphorylation event triggers downstream signalling through phospholipase C-gamma (PLCγ) and phosphoinositide 3-kinase (PI3K)/Akt pathways. Cell-based reporter assays demonstrate sustained receptor activation lasting several hours post-compound exposure. FAK/Paxillin Signalling Network Focal adhesion kinase (FAK) represents a critical downstream target in BPC-157's mechanism of action. The compound induces FAK autophosphorylation at Tyr397, creating docking sites for Src family kinases and subsequent activation of the FAK/Src complex. This activation promotes phosphorylation of paxillin at multiple tyrosine residues, facilitating assembly of focal adhesion complexes. Time-course experiments in endothelial cell models reveal BPC-157-induced FAK activation occurs within 15-30 minutes of compound exposure, with peak phosphorylation observed at 1-2 hours. The sustained nature of FAK/paxillin signalling distinguishes BPC-157 from other VEGFR2 agonists, suggesting unique pharmacokinetic properties within cellular systems. Nitric Oxide Synthase Pathway Modulation eNOS Activation Mechanisms BPC-157 demonstrates potent activation of endothelial nitric oxide synthase (eNOS) through both calcium-dependent and calcium-independent mechanisms. The compound enhances eNOS phosphorylation at Ser1177 via Akt-mediated signalling, while simultaneously reducing inhibitory phosphorylation at Thr495. This dual regulatory mechanism results in sustained nitric oxide production in endothelial cell cultures. Nitrite/nitrate assays confirm BPC-157-induced NO production follows a dose-response relationship, with EC50 values in the nanomolar range across multiple endothelial cell lines. The temporal profile of NO release exhibits biphasic kinetics, with initial calcium-dependent activation followed by prolonged Akt-dependent sustained production. Downstream NO Signalling Nitric oxide generated through BPC-157 stimulation activates soluble guanylyl cyclase (sGC), leading to cyclic GMP (cGMP) accumulation. Cell-based cGMP assays demonstrate 3-5 fold increases in intracellular cGMP levels within 10 minutes of BPC-157 exposure. This elevation persists for 2-4 hours, indicating sustained pathway activation. The cGMP-protein kinase G (PKG) axis activated by BPC-157 subsequently modulates multiple downstream targets, including phosphodiesterases, ion channels, and transcription factors. Transcriptomic analysis reveals upregulation of genes associated with cellular adhesion, migration, and survival pathways. Gastrointestinal Cell Model Studies Intestinal Epithelial Cell Systems BPC-157 research utilises various intestinal epithelial cell models, including Caco-2, IEC-6, and primary enterocyte cultures. These systems enable investigation of the compound's effects on epithelial barrier function, tight junction integrity, and cellular migration patterns. Transepithelial electrical resistance (TEER) measurements demonstrate BPC-157's ability to enhance barrier function in compromised epithelial monolayers. Wound healing assays using scratch-wound methodology reveal enhanced epithelial cell migration rates following BPC-157 treatment. Time-lapse microscopy studies quantify closure rates, with treated cultures exhibiting 40-60% faster gap closure compared to control conditions. Gastric Cell Culture Applications Primary gastric epithelial cell cultures and gastric organoid systems provide physiologically relevant models for BPC-157 research. These three-dimensional culture systems maintain cellular architecture and functional characteristics similar to native gastric tissue. BPC-157 treatment promotes organoid growth and branching morphogenesis through VEGFR2-dependent mechanisms. Enzyme kinetic studies in gastric cell models reveal BPC-157's influence on pepsinogen activation and gastric lipase activity. The compound demonstrates protective effects against oxidative stress-induced cellular damage through enhanced antioxidant enzyme expression and reduced reactive oxygen species accumulation. Research Summary BPC-157 exhibits complex multi-target pharmacology centred on VEGFR2 receptor activation and subsequent engagement of FAK/paxillin and NO synthase pathways. Cell-based assay systems demonstrate the compound's ability to modulate endothelial function, enhance epithelial barrier integrity, and promote cellular survival mechanisms. Gastrointestinal cell models specifically highlight BPC-157's tissue-selective effects on epithelial function and protective enzyme systems. These in vitro findings establish a foundation for understanding BPC-157's molecular mechanism of action across diverse cellular targets and tissue-specific applications in research settings. All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. Hexarelin TB-500 Epithalon Ipamorelin Tirzepatide CJC-1295 DAC PT-141 Semaglutide Selank BPC-157 Sermorelin Melanotan 2 IGF LR3 Tesamorelin AICAR IGF-DES GHRP 2 Albuterol Tamoxifen Letrozole Clomiphene Tadalafil Clenbuterol Anastrozole Finasteride Exemestane Sildenafil Yohimbine Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows Already a customer? Sign In Create Account All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act. Sarms Stacks Research Liquids Albuterol 5MG/ML | 30ML with dropper Anastrozole 1.5MG/ML | 30ML with dropper Clomiphene 50MG/ML | 30ML with dropper Finasteride 5MG/ML | 30ML with dropper Letrozole 3.5 MG/ML | 30ML with dropper LiquiCia 30MG/ML | 30ML with dropper LiquiCia T50 50MG/ML | 30ML with dropper LiquiClen 200MCG/ML | 30ML with dropper Liquistane / Exemestane 25MG/ML | 30ML with dropper LiquiTamo 20MG/ML | 30ML with dropper LiquiVia 25MG/ML | 30 ML with dropper T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper Toremifene Citrate 60MG/ML | 30ML with dropper Yohimbine HCL 10MG/ML | 30ML with dropper Research Peptides Aicar 50MG BPC-157 + TB-500 Blend 2mg ea/ 4MG BPC-157 5MG CJC-1295 + DAC 2MG CJC-1295 | No DAC 2MG Epithalon 10MG Frag Premium 176-191 5MG GHK-CU Copper Peptide 50MG GHRP-2 5MG GHRP-6 5MG Hexarelin 5MG IGF-1 DES 1MG IGF-1 LR3 1MG Ipamorelin 5MG Melanotan 2 10MG NAD+ 500MG PT-141 / Bremelanotide 10MG GLP-1/GIP/GCG (RT) Selank 5MG GLP1 (SM) Sermorelin 5MG TB-500 5MG GIP/GLP-1 (TZ) PDE5 Inhibitors GLP-1 Diluents Bacteriostatic Water 10ML

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

BPC-157 vs Traditional Growth Factors: A Side-by-Side Research Comparison

A meaningful way to crystallize the answer to the question — is BPC-157 a growth factor — is to directly compare its characteristics to those of well-established growth factors ac…

Comparison

BPC 157 vs. Other Peptides: A Quick Comparison

It's helpful to see where BPC 157 fits within the broader landscape of research peptides being studied for recovery and inflammation. It's not the only player on the field, and di…